Analysts have clear opinions on NGM.

Based on 4 analysts offering 12 month price targets for NGM Biopharmaceuticals in the last 3 months. The average price target is $23.67 with a high forecast of $25.00 and a low forecast of $22.00. The average price target represents a 35.26% increase fro
NGM Biopharmaceuticals, Inc. (NGM) is followed by 4 analysts on the street.

Ritu Baral from Cowen & Co. rates it a Buy with a target of $25.00.

Similarly, 18 days ago Paul Choi of Goldman Sachs Reiterated a Buy with a target of $22.00.

The consensus on the street is Strong Buy.

What does NGM Biopharmaceuticals, Inc.(NGM) do ?
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohep

NGM Biopharmaceuticals, Inc. (NGM) Insider Trades

Multiple company employees have indulged in significant insider trading. NGM Biopharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, 10%, Svennilson Peter : P – Purchase(+$180) of NGM in the trading session of 2019-11-11.

Dir, 10% Goeddel David V : P – Purchase(+$180) of NGM in the trading session of 2019-11-11.

10% Column Group L P : P – Purchase(+$180) of NGM Biopharmaceuticals, Inc. in the trading session of 2019-11-11.